Skip navigation

Save the Children, drug co. GSK in new partnership

GlaxoSmithKline is giving Save the Children $23 million and entering into a five-year partnership with the charity to try to save the lives of 1 million children. Full story

Impax, GSK end Parkinson's disease partnership

(Reuters) - Impax Laboratories Inc said partner GlaxoSmithKline Plc ended their collaboration on Impax's experimental Parkinson's disease drug due to regulatory and launch delays in the countries in which GSK has rights to market the drug. Full story

GSK to partner with venture capital firm for drug discovery

(Reuters) - GlaxoSmithKline said on Monday it will partner with venture capitalists Avalon Ventures in a deal worth up to $495 million to fund as many as 10 drug-discovery startup companies over the next three years. Full story

FDA delays approval of GSK bird flu vaccine

LONDON (Reuters) - Regulators have delayed approval of an H5N1 bird flu vaccine from GlaxoSmithKline, designed to be used in a pandemic. Full story

GlaxoSmithKline files for European approval of diabetes drug albiglutide

LONDON (Reuters) - Britain's biggest drugmaker GlaxoSmithKline said on Thursday it had filed for European approval of its new once-weekly diabetes drug albiglutide, as tries to gain a foothold in a crowded market. Full story

Piper Jaffray says GSK could buy out Theravance

(Reuters) - Shares of Theravance Inc <THRX.O> rose as much as 18 percent after a brokerage said a positive outcome on the approval of its respiratory drugs could lead to a takeover of the drugmaker, which is one-quarter owned by GlaxoSmithKline Plc <GSK.L>. Full story

Sponsored Links

Articles

Bankers thirsty for juicy GlaxoSmithKline drinks deal

Europe faces cost cuts as GSK promises return to growth

Galapagos says GSK starting trials of its new drug

GSK promises to publish detailed drug trial data

UK families face court fight over GSK diabetes drug

GSK details hopes for 14 pipeline drugs in 2013-14

GSK and J&J lead rivals in drug access for poor

Video

  Glaxo's CEO Predicts Growth in 2013

Andrew Witty, CEO of GlaxoSmithKline, discusses his company's 2012 earnings and explains why he is optimistic about the company's restructuring plans in Europe.

  Faber Report: GSK's Acquires Human Genome Science

CNBC's David Faber reports the latest details on GlaxoSmithKline's takeover bid for Human Genome Science.

  July 2: Nightly News Monday broadcast

Triple digit heat follows power outages; Where homes become ovens; Inside Colorado’s burn zone; GlaxoSmithKline pays $3 billion to settle fraud case; Dual-engine failure caused jet crash; Pena Nieto promises to jumpstart Mexico’s economy; Improving firefighter safety; Statue of Liberty replica moves

advertisement | ad info

Related Photos

Signage is pictured on the company headquarters of GlaxoSmithKline in west London
Signage is pictured on the company headquarters of GlaxoSmithKline in west London

Signage is pictured on the company headquarters of GlaxoSmithKline in west London July 21, 2008. GlaxoSmithKline announce their half yearly results on Wednesday July 23. REUTERS/Toby Melville

A GlaxoSmithKline logo is seen outside one of its buildings in west London, ahead of company results
A GlaxoSmithKline logo is seen outside one of its buildings in west London, ahead of company results

A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008. REUTERS/Toby Melville

GlaxoSmithKline Chief Executive Andrew Witty speaks at the Global Investment Conference in London
GlaxoSmithKline Chief Executive Andrew Witty speaks at the Global Investment Conference in London

GlaxoSmithKline Chief Executive Andrew Witty speaks at the Global Investment Conference in London July 26, 2012. REUTERS/Neil Hall